EMA Authorised: Wezenla (ustekinumab) — Amgen Technology (Ireland) UC

View source ↗

Summary

EU authorization for Wezenla, a ustekinumab product from Amgen Technology (Ireland) UC, indicated for psoriasis, psoriatic arthritis, and Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Wezenla (ustekinumab)

Snippet

Status: Authorised. Therapeutic area: Psoriasis;Arthritis, Psoriatic;Crohn Disease. MAH: Amgen Technology (Ireland) UC. Decision date: 13/02/2026